Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks In Europe Shake Off US Poll Uncertainty

Wed, 04th Nov 2020 12:12

(Alliance News) - Stock prices in Europe were higher on Wednesday afternoon, with markets "remarkably calm" despite the US election still being undecided long after polls in the US have closed.

In London, the FTSE 100 index was up 32.30 points, or 0.6% at 5,819.07 midday Wednesday. The blue-chip index had fallen by 1.0% to a low of 5,731.07 during a frenetic open but soon recovered.

The mid-cap FTSE 250 was up 115.10 points, or 0.7%, at 17,606.80 at midday. The AIM All-Share was up 6.29 points, 0.7%, at 965.67.

The Cboe UK 100 index was up 0.7% at 578.61. The Cboe 250 was up 0.7% at 14,845.61. The Cboe Small Companies grew 0.7% at 9,566.20.

The CAC 40 stock index in Paris was up 0.4%, and Frankfurt's DAX 30 up 0.1%.

"Markets are overall remarkably calm so far today despite maximum election uncertainty," noted AxiCorp analyst Stephen Innes.

"Before the election, many investors would have seen a Biden/Republican Senate as the worst outcome due to small fiscal stimulus combined with higher taxes and more regulation. And yet this scenario looks the most likely now and the market seems OK with that outcome."

President Donald Trump prematurely declared victory and sought Supreme Court intervention to stop vote-counting – even as his Democratic rival Joe Biden voiced confidence in his own chances.

In a divisive election cast under the shadow of the coronavirus pandemic that has claimed more than 230,000 lives in the US, Trump appeared to have avoided a Democratic wave predicted by some polls but he still needs key states to secure another four-year term.

Television networks predicted that Biden would be the first Democrat in 24 years to win Arizona, seizing on the southwestern state's changing demographics and the popularity of astronaut Mark Kelly who was projected to win a Senate seat.

But no other states so far have flipped, and Trump won an early prize in Florida, where his hard line against Latin American leftists helped him make inroads among Cuban Americans.

A New York Times tally has Biden currently leading the way with 227 electoral college votes, compared to Trump's 213, though both are still short of the magic 270 mark with a number of key states yet to declare.

US stock index futures were largely in the green, with just the Dow Jones Industrial Average pointed lower, at 0.2%. The S&P 500 was called 0.3% higher and the Nasdaq Composite by a much-higher 1.9%.

A "blue wave" in favour of the Democrats may have meant tighter regulation for the tech sector, but Republicans looked likely to hold the Senate.

Despite retaining the House of Representatives, the path for Democrats to flip control of the US Senate narrowed sharply, after two key Republicans facing tough reelection battles claimed victory. Democrats flipped two Senate seats in western Colorado and Arizona states on Tuesday, networks projected, but Republicans ousted a vulnerable Democrat in Alabama.

In pre-market trade in New York, Facebook gained 2.5%, Apple was up 2.7%, and Google owner Alphabet was 2.9% higher.

In London, pharmaceutical firms were among the better blue-chip performers.

AstraZeneca climbed 4.9%, Hikma 4.1% and GlaxoSmithKline rose 2.3%. A Democratic president and Senate also might have brought more regulation for the pharmaceutical industry.

Royal Mail topped the FTSE 250s, up 8.8% after JPMorgan raised the UK postal service provider to Overweight from Neutral.

Elsewhere, Marks & Spencer was up 5.2%. The retailer's interim performance was better than expected, despite swinging to a pretax loss of GBP87.6 million from a GBP158.8 million profit.

Revenue for the six months to September declined 16% to GBP4.09 billion from GBP4.86 billion a year before.

Stobart Group shares rose 5.1%. The logistics, energy and aviation firm's pretax loss ballooned to GBP77.4 million from GBP15.5 million though the market took heart from "improving trends" at Stobart Energy, as well as the company's plans to exit Stobart Air.

"The group is seeking to exit that business in early course. To that end, it is engaging actively with parties interested in acquiring its stake and with Aer Lingus to enter a new commercial arrangement beyond December 2022 as part of this process," Stobart explained.

Elsewhere on the main market, construction firm Morgan Sindall rose 5.2%. The company said annual pretax profit will top its GBP50 million to GBP60 million guidance range.

Morgan Sindall declared a 21.0 pence per share interim payout, in line with 2019's interim dividend, having put off a decision on a dividend at the time of its half-year results in August.

Commenting on the upcoming lockdown in England, the company said it does not expect any material disruption.

Construction firms such as Morgan Sindall are able to continue operating during the upcoming English lockdown.

In Westminster, UK members of Parliament are to vote on the new four-week coronavirus restrictions, amid warnings the National Health Service will be overwhelmed with thousands more deaths unless action is taken.

With Labour backing the new restrictions, which are due to come into force on Thursday, the government is expected comfortably to win Wednesday's Commons vote.

Nevertheless, UK Prime Minister Boris Johnson is facing a revolt by some Tory backbenchers angry at the impact on civil liberties and the economic damage the measures will cause.

Ahead of the Commons vote, Johnson warned of "fatalities running in the thousands" if no action was taken as cases across the country continued to rise.

At the same time he sought to offer hope, telling Tuesday's Cabinet meeting that the R number – the reproduction rate of the virus – was "only just above 1" and the new measures would bring it back below that threshold.

Turning to forex, the dollar had a strong start to the European session on Wednesday though its gains have eased as New York prepares to open.

The pound was quoted at USD1.3001 on Wednesday midday, down from USD1.3070 at the London equities close on Tuesday. However, sterling was as low as USD1.2915 earlier in trading.

The euro slipped to USD1.1704, from USD1.1729 late Tuesday.

Versus the yen, the dollar fetched JPY104.60, up from JPY104.50 at the London market close on Tuesday.

The UK services sector grew at a much slower pace in October as the hospitality sector was hit by tighter Covid-19 restrictions, according to final survey data.

IHS Markit/CIPS UK services purchasing managers' index business activity index registered 51.4 points in October, staying above the 50.0 no-change mark but down sharply from 56.1 in September.

The UK composite output index - a weighted average of the services score and Monday's manufacturing PMI - came in at 52.1 in October, the worst reading in four months and down from 56.5 in September.

The eurozone's private sector was treading water in October, as manufacturing growth was offset by a decline in the services industry. The single-currency bloc's services activity index dropped to 46.9 in October, the weakest performance since May and painting a troubled picture for the hospitality industry.

"The eurozone data tells a more worrying story and, given the slight lead compared to the UK in terms of implementing a return of increased Covid measures, we feel this may be a signal of what is to come," analysts at broker Jefferies said.

Still to come on Wednesday, the US services PMI will be released at 1445 GMT. Before that, ADP employment figures are released at 1315 GMT. These are an important precursor to the key October nonfarm payrolls data due Friday.

By Eric Cunha; ericcunha@alliancenews.com;

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.